Table 1.
Demographic and clinical characteristics of the cohort
| Characteristics | Entire Cohort N (%) |
SPM Patients* including NMSC N (%) |
SPM Patients** excluding NMSC N (%) |
|---|---|---|---|
| Number of patients | 841 | 60 | 42 |
| Gender | |||
| Female | 330 (39%) | 17 (28%) | 12 (29%) |
| Male | 511 (61%) | 43 (72%) | 30 (71%) |
| Race/ethnicity | |||
| Non-Hispanic Caucasian | 511 (61%) | 49 (82%) | 31 (74%) |
| Hispanic | 151 (18%) | 5 (8%) | 5 (12%) |
| African American | 107 (13%) | 4 (7%) | 4 (9%) |
| Others | 72 (9%) | 2 (3%) | 2 (5%) |
| Age at ASCT (years) | |||
| Median (range) | 56 (18–77) | 59 (32–77) | 56 (32–69) |
| Mean (SD) | 55 (8.9) | 57 (9.4) | 55 (9.5) |
| Age at MM diagnosis (years) | |||
| Median (range) | 55 (18–76) | 57 (31–76) | 54 (31–68) |
| Mean (SD) | 54 (8.9) | 55 (9.4) | 53 (9.3) |
| Year of MM diagnosis | |||
| 1983–1999 | 206 (24%) | 30 (50%) | 25 (60%) |
| 2000–2004 | 301 (36%) | 20 (33%) | 11 (26%) |
| 2005–2009 | 334 (40%) | 10 (17%) | 6 (14%) |
| Year of ASCT | |||
| 1989–1999 | 133 (16%) | 22 (37%) | 18 (43%) |
| 2000–2004 | 278 (33%) | 22 (37%) | 15 (36%) |
| 2005–2009 | 430 (51%) | 16 (27%) | 9 (21%) |
| Source of stem cell | |||
| Peripheral blood | 841 (100%) | 60 (100%) | 42 (100%) |
| Disease status at ASCT | |||
| Partial remission | 578 (69%) | 44 (73%) | 33 (79%) |
| Stable disease | 115 (14%) | 9 (15%) | 4 (9%) |
| Complete remission | 111 (13%) | 7 (12%) | 5 12%) |
| Progressive disease | 31 (4%) | 0 (0%) | 0 (0%) |
| Unknown | 6 (0.7%) | 0 (0%) | 0 (0%) |
| Transplantation type | |||
| Single autologous | 527 (63%) | 32 (53%) | 22 (55%) |
| Tandem autologous | 229 (27%) | 18 (30%) | 12 (29%) |
| Multiple | 85 (10%) | 10 (17%) | 7 (17%) |
*
Including non-melanoma skin cancer
**
Excluding non-melanoma skin cancer
NMSC=non-melanoma skin cancer, ASCT=autologous stem cell transplantation, SD=standard deviation, SPM=second primary malignancy